SNN
Smith+Nephew launch next generation LEAF Patient Monitoring System - an innovative pressure injury prevention platform delivering proven clinical impact
Article Summary
HOLD- Smith+Nephew plc (NYSE: SN) announced the US launch of next generation LEAF Patient Monitoring System, a data-driven pressure injury prevention platform designed to help health care providers tackle growing burden of hospital-acquired pressure injuries by strengthening protocols and outcomes.
- The LEAF System uses a wearable sensor to monitor patient mobility and provide real-time turn status updates, helping to improve workflow efficiency, turn quality, and protocol adherence.
- The cloud-hosted solution features redesigned and enhanced user interface designed in consultation with multidisciplinary nursing teams to ensure at-risk patients get necessary care at appropriate time.
- The system seamlessly integrates with hospital electronic medical records, helping nurses adhere to turning protocols using real time data and reporting that quickly identifies at- risk patients.
- Each year it monitors over 150,000 patients, reducing odds of HAPIs by up to 73% and delivering up to $1.8 million in estimated savings in one critical care facility.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 6.3% | 25% | 35.0 ptsBelow Screener (6.3%) - Weak growth |
| EPS Growth Next 5Y ? | 9.8% | 25% | 20.0 ptsWeak (9.8%) - Low expectations |
| Target Price Upside ? | 25.1% | 20% | 75.0 ptsSignificant Upside (25.1%) - Target: $36.89 vs Current: $29.48 |
| Gross Margin % ? | 68.0% | 15% | 80.0 ptsVery Healthy (68.0%) - High-quality margins |
| Drawdown from 52-Wk High ? | -24.0% | 15% | 40.0 ptsMild Pullback (-24.0%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About SNN
- Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally.
- The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
- It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
- The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints.
- In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions.
- Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems.
- It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.